Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Oschmann To Succeed Kley At Merck KGaA

by Marc S. Reisch
October 19, 2015 | A version of this story appeared in Volume 93, Issue 41

Oschmann
[+]Enlarge
Credit: Merck KGaA
Stefan Oschmann, 58, who will become chairman and CEO of Merck KGaA in April 2016.
Credit: Merck KGaA

Stefan Oschmann, 58, will become chairman and CEO of Merck KGaA in April 2016 after the retirement of Karl-Ludwig Kley, 64. Oschmann, who became deputy CEO at the beginning of this year, previously headed the firm’s pharma business. The announcement comes as Merck prepares to finalize the acquisition of the lab supply firm Sigma-Aldrich. In a separate simplification move, Merck is dropping the Serono and Millipore designations for its drug and lab supply businesses except in the U.S. and Canada, where they will continue to operate as EMD Serono and EMD Millipore.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.